HY-0102 / HyaMab - LARVOL DELTA

YL-13027 and/or HY-0102 Combined With AG Regimen Chemotherapy for Metastatic Pancreatic Cancer (clinicaltrials.gov) - P1/2 | N=120 | Not yet recruiting | Sponsor: Shanghai YingLi Pharmaceutical Co. Ltd.

Metastases • New P1/2 trial • Gastrointestinal Cancer • Hepatology • Oncology • Pancreatic Cancer • Solid Tumor

A Study of HY-0102 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=50 | Recruiting | Sponsor: Shanghai YingLi Pharmaceutical Co. Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Monotherapy • Colorectal Cancer • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Solid Tumor

HY-0102 Monotherapy in Patients With Locally Advanced/Metastatic Solid Tumours (clinicaltrials.gov) - P1 | N=17 | Completed | Sponsor: Shanghai HyaMab Biotech Co.,Ltd. | Active, not recruiting ➔ Completed | N=32 ➔ 17

Enrollment change • Metastases • Monotherapy • Trial completion • Oncology • Solid Tumor • HLA-E • KLRC1

A Study of HY-0102 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=50 | Not yet recruiting | Sponsor: Shanghai YingLi Pharmaceutical Co. Ltd.

Metastases • Monotherapy • New P1 trial • Colorectal Cancer • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Solid Tumor

HY-0102 Monotherapy in Patients With Locally Advanced/Metastatic Solid Tumours (clinicaltrials.gov) - P1 | N=32 | Active, not recruiting | Sponsor: Shanghai HyaMab Biotech Co.,Ltd. | Trial primary completion date: May 2023 ➔ Dec 2023

Metastases • Monotherapy • Trial primary completion date • Oncology • Solid Tumor

HY-0102 Monotherapy in Patients With Locally Advanced/Metastatic Solid Tumours (clinicaltrials.gov) - P1 | N=32 | Active, not recruiting | Sponsor: Shanghai HyaMab Biotech Co.,Ltd. | Recruiting ➔ Active, not recruiting

Enrollment closed • Metastases • Monotherapy • Oncology • Solid Tumor

HY-0102 Monotherapy in Patients With Locally Advanced/Metastatic Solid Tumours (clinicaltrials.gov) - P1 | N=32 | Recruiting | Sponsor: Shanghai HyaMab Biotech Co.,Ltd. | Not yet recruiting ➔ Recruiting | Trial completion date: Jun 2023 ➔ Dec 2023 | Trial primary completion date: Nov 2022 ➔ Mar 2023

Enrollment open • Monotherapy • Trial completion date • Trial primary completion date • Oncology • Solid Tumor